AbbVie (ABBV): A Tier Three Dividend Growth Stock

Great companies don't avoid challenges.

They overcome them.

Few businesses demonstrate that better than AbbVie.

Founded in 2013 after being spun off from Abbott Laboratories, AbbVie quickly became one of the world's premier biopharmaceutical companies. The company develops medicines across immunology, oncology, neuroscience, aesthetics, and eye care, with well-known brands including Skyrizi, Rinvoq, Botox, Vraylar, and several leading cancer therapies.

For years, one drug — Humira — dominated the company's revenue.

When patent protection began expiring, many investors questioned whether AbbVie could continue growing.

Management answered that question with one of the most impressive product transitions in modern healthcare.

Key Statistics

• Ticker: ABBV
• Tier: Tier Three
• Industry: Biopharmaceuticals
• Market Capitalization: Approximately $350 billion+
• Consecutive Years of Dividend Increases: 53 years*
• Dividend Aristocrat Status: Yes
• Dividend King Status: Yes

*AbbVie was spun off from Abbott Laboratories in 2013. When combined with Abbott's dividend history, shareholders have enjoyed more than five decades of consecutive annual dividend increases, making this one of the longest-running dividend growth stories in the healthcare sector.

Why ABBV Fits Tier Three

Tier Three is where the focus shifts toward building dependable income that continues growing faster than inflation.

That doesn't mean buying every stock with a large dividend.

It means building a portfolio of businesses capable of producing high-quality income.

Across my Tier Three portfolio, the objective is to average approximately a 5% starting dividend yield while targeting around 4% to 5% annual dividend growth.

The important word is average.

Some Tier Three companies, like Procter & Gamble and Coca-Cola, may offer lower yields because of their exceptional stability.

Others, like AbbVie, often provide yields comfortably above the portfolio average.

Together, those companies create an income stream that's both dependable and diversified.

AbbVie is one of the companies that helps make that possible.

Reinvention Is the Story

One of the reasons I admire AbbVie is that management refused to let the company become dependent on a single product.

Humira became one of the best-selling prescription drugs in history.

Eventually, every investor knew patent expiration was coming.

Instead of hoping for the best, management invested heavily in the next generation of therapies.

Today, Skyrizi and Rinvoq have become major growth engines, helping offset Humira's decline while expanding AbbVie's leadership in immunology.

At the same time, the company strengthened its portfolio through acquisitions that brought products like Botox into the business.

That isn't luck.

That's disciplined strategic planning.

For dividend investors, management execution matters just as much as today's dividend yield.

Why It Belongs in Tier Three Instead of Tier Two

AbbVie illustrates another important principle of the DGI Crab framework.

Tier Two companies generally emphasize balancing current income with faster future growth.

Tier Three companies shift the emphasis toward dependable income while continuing to grow that income steadily over time.

AbbVie typically offers a dividend yield well above most Tier Two companies.

Management has also demonstrated a willingness to return substantial cash flow directly to shareholders while continuing to invest billions in research and development.

That's exactly what I want from a Tier Three holding.

Meaningful income today. Continued dividend growth tomorrow. And a management team that's willing to make difficult decisions to protect the company's long-term future.

Healthcare Never Stops

One reason healthcare remains one of my favorite sectors for Tier Three is simple.

People don't stop needing medicine during recessions.

Cancer treatments continue.

Autoimmune diseases still require therapy.

Neurological disorders don't disappear because the economy slows down.

Demand may shift between products, but the need for innovative healthcare remains constant.

AbbVie operates in some of the most important therapeutic areas in medicine.

That gives me confidence that the company will continue generating the cash flow necessary to support both research and shareholder returns for many years to come.

Final Thoughts from the DGI Crab

AbbVie has already overcome the challenge that many investors believed would define its future.

Instead of allowing Humira's patent expiration to become the end of the story, management built the company's next chapter.

For a Tier Three DGI Crabber, that's exactly the type of business I want generating retirement income.

A generous dividend. Steady dividend growth. Strong free cash flow. And a management team that has already proven it can adapt when circumstances change.

That's what I call high-quality income.